Two large clinical trials (HOPE 2 and NORVIT) examined whether lowering homocysteine (an amino acid linked to cardiovascular risk) through B vitamin supplementation improved outcomes in high-risk patients. Despite significantly lowering homocysteine levels, supplementation provided no cardiovascular benefit except modest stroke reduction. The trials challenged previous assumptions that homocysteine reduction automatically improved outcomes, suggesting that elevated homocysteine may be a marker rather than cause of cardiovascular disease.
This research has implications for MS patients: B vitamins (folic acid, B12, B6) lower homocysteine but don't improve cardiovascular outcomes if given solely for that purpose. However, B vitamins support many other functions including neurological health, immune regulation, and myelin synthesis. For MS patients, B vitamins remain important for multiple reasons beyond homocysteine reduction. The research suggests that while homocysteine elevation might indicate need for investigation, direct supplementation targeting homocysteine reduction isn't sufficient preventive therapy. MS patients benefit from comprehensive B vitamin supplementation supporting overall neurological function rather than focused strategies targeting single biomarkers.
